Treatment outcomes using CyberKnife for brain metastases from lung cancer. (25th October 2014)

• Record Type: Journal Article
• Authors: Tamari, Keisuke; Suzuki, Osamu; Hashimoto, Naoya; Kagawa, Naoki; Fujiwara, Masateru; Sumida, Iori; Seo, Yuji; Isohashi, Fumiaki; Yoshioka, Yasuo; Yoshimine, Toshiki; Ogawa, Kazuhiko
• Is Part Of: Journal of radiation research. Volume 56:Number 1(2015:Jan.)
• Page Start: 151
• Page End: 158
• Publication Date: 2014-10-25
• Subjects: stereotactic radiosurgery -- CyberKnife -- brain metastases -- lung cancer; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rru092
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract : We investigated the clinical outcomes following treatment using stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) for brain metastases from lung cancer. A total of 67 patients with 109 brain metastases from lung cancer treated using CyberKnife between 1998 and 2011 were retrospectively analyzed. SRS (median dose, 24 Gy) was used to treat 79 lesions, and 3-fraction SRT (median dose, 30 Gy) was used to treat 30 lesions. The median follow-up time was 9.4 months (range, 0.4–125 months). The 1-year local control rate was 83.3%, and the 1-year distant brain failure rate was 30.1%. The median survival time was 13.1 months, and the 1- and 3-year overall survival (OS) rates were 54.8% and 25.9%, respectively. On multivariate analysis, three factors were found to be statistically significant predictors of OS: (i) presence of uncontrolled primary disease [hazard ratio (HR) = 3.04; P = 0.002]; (ii) Brinkman index (BI) ≥ 1000 (HR = 2.75; P = 0.007); and (iii) pulmonary metastases (HR = 3.54; P = 0.009). Radionecrosis and worsening of neurocognitive function after radiosurgery were observed in 5 (7%) and 3 (4%) patients, respectively. Our results indicated that SRS/SRT for brain metastases from lung cancer was effective. Uncontrolled primary disease, high BI, and pulmonary metastases at treatment were significant risk factors for OS.